Načítá se...

Analyses of CD20 Monoclonal Antibody–Mediated Tumor Cell Killing Mechanisms: Rational Design of Dosing Strategies

Since approval of rituximab for treatment of B cell non-Hodgkin lymphoma, development of monoclonal antibodies (mAbs) for cancer treatment and elucidation of their cytotoxic mechanisms have been subject to intense investigations. Compelling evidence indicates that rituximab and another CD20 mAb, ofa...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Taylor, Ronald P., Lindorfer, Margaret A.
Médium: Artigo
Jazyk:Inglês
Vydáno: The American Society for Pharmacology and Experimental Therapeutics 2014
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4201137/
https://ncbi.nlm.nih.gov/pubmed/24944188
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/mol.114.092684
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!